Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | GPR174 | Q9BXC1 | 9/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30258446 | 1.00 | MAPT (0.63) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL30965583 | 0.91 | MAPT (0.77) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL8221482 | 0.91 | MAPT (0.60) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL24480736 | 0.90 | GPR174 (0.54) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL30965670 | 0.90 | MAPT (0.59) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL3927908 | 0.90 | MAPT (0.76) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL521504 | 0.90 | MAPT (0.59) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL31487436 | 0.90 | MAPT (0.59) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL31487397 | 0.89 | MAPT (0.52) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL30965662 | 0.89 | MAPT (0.52) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3976604-B1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2026-01-21 | — | — | EP | disclosed |
| EP-4658658-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024162828-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2024-08-08 | — | — | WO | disclosed |
| US-20230092890-A1 | 1, 3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) | 2023-03-23 | — | — | US | disclosed |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
| EP-3976604-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2022-04-06 | — | — | EP | disclosed |
| CN-113924296-A | 1,3, 4-oxadiazole derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | 株式会社钟根堂 | 2022-01-11 | — | — | CN | disclosed |
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | NUVATION BIO INC. (US) | 2021-11-16 | — | — | US | disclosed |
| CN-112334451-A | Heterocyclic compounds as kinase inhibitors | 诺维逊生物股份有限公司 | 2021-02-05 | — | — | CN | disclosed |
| EP-3752491-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Nuvation Bio Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-7786128-B2 | Indole or benzimidazole derivatives as CB1 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2010-08-31 | — | — | US | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| US-20080234290-A1 | NEW INDOLE OR BENZIMIDAZOLE DERIVATIVES AS CB1 INVERSE AGONISTS | BLEICHER KONRAD | 2008-09-25 | — | — | US | disclosed |
| EP-1807398-B1 | NEW INDOLE OR BENZIMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-06-25 | — | — | EP | disclosed |
| US-7384945-B2 | Indole or benzimidazole derivatives as CB1 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1807398-A1 | NEW INDOLE OR BENZIMIDAZOLE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006045478-A1 | NEW INDOLE OR BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-04 | — | — | WO | disclosed |
| US-20060089367-A1 | New indole or benzimidazole derivatives as CB1 inverse agonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089367-A1 | New indole or benzimidazole derivatives as CB1 inverse agonists | CNR1, CNR2, GPR119 | MAPT 2931/4885ALDH1A1 1339/4885SMN1; SMN2 3382/4885 |
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | CDK6, CDK4, CDK9 | MAPT 3390/4885ALDH1A1 2534/4885SMN1; SMN2 3306/4885 |
| US-20230092890-A1 | 1, 3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | HDAC6, HDAC1, HDAC2 | MAPT 974/4885ALDH1A1 154/4885SMN1; SMN2 2013/4885 |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | MAPT 3156/4885ALDH1A1 2992/4885SMN1; SMN2 2917/4885 |
| US-20080234290-A1 | NEW INDOLE OR BENZIMIDAZOLE DERIVATIVES AS CB1 INVERSE AGONISTS | CNR1, CNR2, GPR119 | MAPT 2931/4885ALDH1A1 1339/4885SMN1; SMN2 3382/4885 |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | MAPT 3109/4885ALDH1A1 779/4885SMN1; SMN2 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.